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malpractice insurance company: one in chronic hepatitis
C and another in primary biliary cirrhosis [7]. We devel-
oped research on biomarkers in order to prevent these
and other serious side eﬀects. Given the increasing inci-
dence and mortality of some liver diseases, screening
for advanced ﬁbrosis in the general population is a major
public health challenge. This can only be achieved
through a moratorium on liver biopsy as a ﬁrst-line esti-
mate of injury in chronic liver diseases and the validation
of non-invasive markers [8]. While we agree that liver
biopsy (of 40 mm) remains the best reference standard,
it should only be used when all available non-invasive
methods have failed to convince the clinician.
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The letter by Poynard and colleagues deserves several
comments. Like Mehta et al., we agree that when taking
liver biopsy as a reference, any non-invasive test should
not reach a higher AUROC than the liver biopsy itself,
mainly due to the fact that misclassiﬁcation can occur in
staging ﬁbrosis with biopsy [1,2]. The highest AUROC
that can be reached is however unclear and clearly depen-
dent on (1) the rate of misclassiﬁcation in staging with
biopsy (2) the conditional relationship between non-inva-
sive markers and liver histology (3) the internal perfor-
mance of the marker. Interestingly, a recent meta-
analysis of Fibroscan showed AUROC of 0.94 for diag-
nosis of cirrhosis and 0.89 for severe ﬁbrosis taking biopsy
as a reference [3]. These very highAUROCvalues are cer-
tainly not related to a lack of power (more than 10,000 pa-
tients were pooled) or faking as suggested by Poynard
et al. It simply demonstrates that liver biopsy is an accept-
able gold standard and that some, but not all non-invasive
tools, can compete well with liver biopsy where the diag-
nosis of cirrhosis or advanced ﬁbrosis is concerned.
In contrast to Poynard et al. we do not believe that a
spectrum bias due to diﬀerent prevalence of stages in dif-ferent populations can explain the decrease in the AUR-
OC when changing the deﬁnition of diseased liver or for
distinguishing between two adjacent ﬁbrosis stages. In
fact, any comparison of surrogate markers restricted
to two stages eliminated this spectrum bias! [4]. The
explanation for the low performance of markers for
distinguishing between two adjacent stages is lack of
accuracy, which leads us to reinforce our claim that sur-
rogate markers cannot be used for adequate monitoring
of individual ﬁbrosis staging.
Poynard et al. suggest that validation of non-invasive
test of ﬁbrosis and comparison with histological staging
with biopsy should rely on clinical endpoints. This is of
course ideal and surely adequate for any test that evalu-
ates ﬁbrosis independently of histology. Such is the case
for imaging techniques or assessment of liver stiﬀness.
This remark is less relevant when considering serum
markers of ﬁbrosis. The choice of blood tests included
in the marker’s formulas and their respective weights
in the algorithm are deﬁned through the prism of histo-
logic assessment of ﬁbrosis with liver biopsy. In this sit-
uation, liver biopsy is by deﬁnition the gold standard of
the serum markers and any weakness of the biopsy will
directly decrease the ﬁtness of the algorithm of the ser-
um marker. Because of this conditional relationship, ser-
um marker performance should at best approach
accuracy of liver biopsy. Therefore, it is rather surpris-
ing to support serum markers, arguing on biopsy weak-
ness when this tool is chosen to deﬁne the formula of
serum markers. Finally, Poynard et al. suggest that
screening for advanced ﬁbrosis is a public health chal-
lenge and this can only be achieved through a morato-
rium of liver biopsy as a ﬁrst-line estimate. Anybody
would agree that screening of advanced ﬁbrosis does
not rely on liver biopsy and that non-invasive tests have
excellent accuracy in this setting but there is a major dif-
ference between screening for advanced ﬁbrosis and
staging ﬁbrosis. Non-invasive tests have shown decep-
tively low performance in this matter with signiﬁcant
overlap between adjacent stages.
The risk of performing a liver biopsy should always
be discussed with regards to the potential beneﬁt for
the patient and in this context any dogmatic statement,
either in favour or against it, is dangerous. Today, anti-
viral therapy has still limited eﬃcacy and is associated
with serious adverse eﬀects. Therefore management of
patients using only a screening procedure for advanced
ﬁbrosis, such as serum markers, will clearly lead to an
obvious loss of opportunities for patients to be
adequately and timely treated, a risk that surpasses the
adverse events of the biopsy.
Therefore, in the present situation, non-invasive ser-
um markers are eﬃcient screening instruments for
advanced ﬁbrosis or cirrhosis but remain a dead end
when addressing the accurate evaluation of liver
damage.
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Pioglitazone as adjuvant therapy in chronic hepatitis C: Sequential
rather than concomitant administration with pegylated interferon
and ribavirin?
To the Editor:
We read with interest the article by Overbeck
et al., published in the August issue of the Journal of
Hepatology [1]. This study investigating pioglitazone as
adjuvant therapy in hepatitis C patients not responding
to pegylated interferon and ribavirin was terminated be-
cause no eﬀect on viral load was observed, despite a de-
crease of the homeostasis model assessment (HOMA)
index in some patients. We believe that there were sev-
eral inadequacies in the study design that may be at
the origin of the negative results. First, the dosage of
pioglitazone (15 mg) was rather low. Second, because
of the delayed eﬀect of pioglitazone on insulin resistance
and steatosis, starting its administration concomitantly
with the antiviral therapy may be untimely [2].
Here, we report the eﬀect of a sequential adminis-
tration of pioglitazone at higher dosage upon retreat-
ment of a patient with chronic hepatitis C and
steatosis who had not responded to a prior regimen
of pegylated interferon and ribavirin. A 43-year-old
man with chronic HCV infection was admitted to
our Department at Saint-Antoine Hospital in Novem-
ber 2004 for liver biopsy. Known risk factor was IV
drug use between 1982 and 1990. The patient had
no previous history of diabetes, dylipidemia or hyper-
tension. Alcohol consumption was discontinued 6
months earlier. Chronic HCV infection was diagnosed
in April 2004 based on positive anti-HCV antibodies
(ELISA) and detectable HCV RNA by RT-PCR
(Amplicor HCV, Roche). At this time, ALT, AST
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